Funding and Grant Support
The Department of Neurology at Wake Forest School of Medicine has been blessed with several grants to support the development and implementation of our HIRREM research program, as outlined below. The primary source of support for this research has been a series of generous grants from The Susanne Marcus Collins Foundation, Inc.
- The initial HIRREM research project (insomnia pilot study, 2011) was
funded by a $26,000 research grant to the Department of Neurology from
Brain State Technologies, LLC. All other funding has been received from
- Unrestricted grants totaling $47,000 were received in 2011 and 2012 from
the Charles H. Tegeler, III, and Martha L. Tegeler Family Trust, which
were used to support the ongoing Developmental Study.
- In 2011, The Susanne Marcus Collins Foundation, Inc., made a research
grant of $120,000 to support a study evaluating HIRREM with episodic
- The Susanne Marcus Collins Foundation, Inc. provided a research grant of
$600,000 in 2012 to help create a formal HIRREM research program, and
build infrastructure, while also supporting both a variety of pilot
projects, as well as the development of a placebo-controlled insomnia
- In 2013, funding from The Susanne Marcus Collins Foundation, Inc.
provided a research grant of $1 million dollars to further expand the
research capabilities and infrastructure, as well as to support
pilot/feasibility projects with conditions such as PTSD, TBI, hot
flashes, ADHD, and Asperger’s/Autism Spectrum Disorders, while also
supporting a placebo-controlled insomnia study.
- In 2013, a gift of $50,000 was received from a foundation which
preferred to remain anonymous, to support work with concussion in
- In 2013, a grant of $107,000 to support a pilot project with military
PTSD was approved and funded by the Enabling Technology Section of the
Office of the Secretary of Defense. Arrival of this funding is pending.
- In 2014, the Susanne Marcus Collins Foundation, Inc. provided a research grant of
$620,000 to fund additional research focused on athletes with persisting
post-concussion symptoms, continuation of the placebo-controlled
insomnia study, and exploratory work in several other settings.